AB Science announced today that results from masitinib study AB12003 in prostate cancer have been presented at the 2021 American Urological Association

NEXT STORY
South Texas Blood & Tissue Center joins nation’s first emergency blood reserve
PREV STORY
Press release Biocartis Group NV: Disclosure of a transparency notification
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

OSE Immunotherapeutics Announces Strategic Multi-Year Research Collaboration with Memorial Sloan Kettering Cancer Center in New York

NANTES, France, June 12, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173);(Mnémo:OSE) today ...

author_avatar
NASDAQ Market News

FIT Biotech Oy: FIT Biotech Oy’s Board of Directors has decided on the issue of Convertible Notes and Warrants – FIT Biotech’s own equity positive with draw down of fourth Tranche

FIT Biotech Oy Company release May 22, 2018 at 3:30 pm EET FIT Biotech ...

author_avatar
NASDAQ Market News

Protalix BioTherapeutics Reports Positive Interim Data from Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis

CARMIEL, Israel, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced ...

author_avatar
NASDAQ Market News